Literature DB >> 1259387

Pharmacological studies with cefamandole in human volunteers.

B R Meyers, B Ribner, S Yancovitz, S Z Hirschman.   

Abstract

Serum and urine concentrations were measured after administration of 0.5-and 1-g doses of cefamandole intramuscularly and intravenously to healthy volunteers. Intramuscular doses of 0.5 and 1 g yielded serum concentrations at 1 h of 14.7 and 35.6 mug/ml, respectively. Significant antibacterial concentrations persisted through h 8. Intravenous doses of 0.5 and 1 g resulted in respective peak serum levels of 21 mug/ml at 45 min and 103 mug/ml at 15 min; these serum levels rapidly declined. Very high urine concentrations were achieved during the first 8 h after injection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1259387      PMCID: PMC429489          DOI: 10.1128/AAC.9.1.140

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Pharmacology of cefazolin in human volunteers.

Authors:  P Nicholas; B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol       Date:  1973 Aug-Sep       Impact factor: 3.126

2.  Cephalexin: pharmacologic evaluation following oral and parenteral administration.

Authors:  P Nicholas; B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol       Date:  1973 Nov-Dec       Impact factor: 3.126

3.  Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

4.  Cephanone: in vitro antibacterial activity and pharmacology in normal human volunteers.

Authors:  B R Meyers; S Z Hirschman; P Nicholas
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

5.  Biological properties of three 3-heterocyclic-thiomethyl cephalosporin antibiotics.

Authors:  W E Wick; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1972-03       Impact factor: 5.191

6.  Cefamandole: antimicrobial activity in vitro of a new cephalosporin.

Authors:  B R Meyers; B Leng; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

7.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

  7 in total
  16 in total

1.  Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells.

Authors:  N J Snyder; L B Tabas; D M Berry; D C Duckworth; D O Spry; A H Dantzig
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.

Authors:  M Barza; S Melethil; S Berger; E C Ernst
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

3.  The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid.

Authors:  C Fernandez Lastra; E L Mariño; A Dominguez-Gil; J M Tabernero; A Gonzalez Lopez; M Yuste Chaves
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics of cefamandole using a HPLC assay.

Authors:  N S Aziz; J G Gambertoglio; E T Lin; H Grausz; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  Evaluation of cefamandole susceptibility testing of Enterobacteriacea by the autobac 1 system.

Authors:  P C de Girolami; L A Maher; M T Booth; D M St George
Journal:  J Clin Microbiol       Date:  1980-10       Impact factor: 5.948

6.  Pharmacokinetics of cefamandole in osseous tissue.

Authors:  R J Lunke; R H Fitzgerald; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

7.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  The pharmacokinetics of cefuroxime after intravenous injection.

Authors:  P E Gower; C H Dash
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

9.  Pharmacokinetics of cefamandole in the presence of renal failure in patients undergoing hemodialysis.

Authors:  G B Appel; H C Neu; M F Parry; M J Goldberger; G B Jacob
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  Pharmacokinetics and safety of cefamandole in infants and children.

Authors:  C T Chang; A J Khan; M M Agbayani; R Jhaveri; I Amin; H E Evans
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.